Biosimilars Market Summary
According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031. Biosimilars, also known as follow-on biologics, are made by a different business but look and work much like the original medicine.
Request Sample PDF at: https://www.alliedmarketresearch.com/request-sample/162
Increase in incidences of diabetes and autoimmune diseases drives the growth of the global biosimilars market. Moreover, favorable government policies and new product launches in the biosimilars industry have supplemented the growth yet more. Moreover, several growth prospects in the developed as well as developing economies have been beneficial for the key players in the industry.
The oncology diseases segment to dominate by 2031-
Based on application, the oncology diseases segment accounted for more than two-fifths of the global biosimilars market share in 2021, and is anticipated to rule the roost by 2031. The same segment would also cite the fastest CAGR of 26.0% throughout the forecast period, due to rise in prevalence of cancer and increase in demand for cost-effective cancer treatment.
Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/162?reqfor=covid
The monoclonal antibodies segment to maintain the lion’s share-
Based on type, the monoclonal antibodies segment held more than one-fourth of the global biosimilars market revenue in 2021, and is expected to lead the trail by 2031. The same segment would also manifest the fastest CAGR of 26.7% from 2022 to 2031. This is due to increase in R&D activities to develop new biosimilars and rise in use of monoclonal antibodies for cancer treatment.
Europe garnered the major share in 2021-
Based on region, Europe held the major share in 2021, generating nearly two-fifths of the global biosimilars market. At the same time, the same region would also grow at the fastest CAGR of 25.9% by 2031. This is attributed to rise in the prevalence of cancer and increase in launches of multiple biosimilars in the region.
Key players in the industry-
Exxon Mobil Corporation
Haihang Industry Co., Ltd.
Kent elastomer products
Kuraray Co.
Shell,Ltd.
SIBUR
Dupont
The Goodyear Tire & Rubber Company
Other Trending Reports in Life Science Domain
How Big Is the Pharmaceutical Primary Packaging Label Market by 2032? Size, Share & CAGR Analysis
Hepatitis Therapeutics Market Size: $19.17 Billion by 2030 | 3.1% CAGR Growth
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
